)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
InnoCare Pharma
InnoCare Pharma (9969) investor relations material
InnoCare Pharma Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary14 Nov, 2025
Executive summary
Operating revenue for January–September 2025 reached RMB1.12 billion, up 59.85% year-over-year, driven by core product orelabrutinib and an exclusive license agreement with Prolium Bioscience Inc.
Gross profit margin improved to 88.8%, a 2.8 percentage point increase from the prior year.
Net loss narrowed to RMB72 million, a 74.78% reduction compared to the same period last year.
Orelabrutinib sales rose 45.77% year-over-year to RMB1.01 billion, with new indications and expanded reimbursement coverage.
Cash and related accounts stood at RMB7.76 billion as of 30 September 2025.
Financial highlights
Operating revenue for Q3 2025 was RMB383.9 million, up 38.09% year-over-year.
Net loss attributable to shareholders for January–September 2025 was RMB64.4 million.
Basic and diluted EPS for the period were both -0.04 RMB.
R&D expenditure totaled RMB676 million, 60.61% of operating revenue, down 27.53 percentage points year-over-year.
Net cash flows from operating activities improved to -RMB84.3 million from -RMB333.1 million a year earlier.
Outlook and guidance
Sufficient cash reserves will support accelerated development of pipeline projects and expansion of treatment options globally.
What factors beyond revenue reduced YTD net loss?
Reason for 27.53% R&D spend % decrease YTD?
What caused the negative YTD investing cash flow?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from InnoCare Pharma
- Orelabrutinib sales rose 30%, driving revenue growth, margin gains, and a 37.6% loss reduction.9969
H1 202423 Jan 2026 - Q3 drug sales up 76.3%, gross margin 86.0%, and net loss halved, led by orelabrutinib.9969Q3 202415 Jan 2026
- Orelabrutinib sales surged 49.1%, driving revenue growth and narrowing annual loss by 29.9%.9969Q4 20243 Dec 2025
- Revenue up 74%, net loss down 87%, with strong pipeline and global expansion progress.9969Q2 202523 Nov 2025
- Q1 2025 delivered 129.9% revenue growth, profitability, and major pipeline and licensing milestones.9969Q1 20252 Jul 2025
- Orelabrutinib and TYK2 assets drive robust growth and late-stage pipeline progress.9969R&D Day 202413 Jun 2025
Next InnoCare Pharma earnings date
Q4 202525 Mar, 2026
InnoCare Pharma
Next InnoCare Pharma earnings date
Q4 202525 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage